Additional effects of medroxyprogesterone acetate on mammary tumors in oophorectomized, estrogenized, DMBA-treated rats

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4583-4587

  Sakamoto, S ^a   Kudo, H ^a   Suzuki, S ^a   Mitamura, T ^a   Sassa, S ^a   Kuwa, K ^a   Chun, Z ^a   Yoshimura, S ^a   Maemura, M ^a   Nakayama, T ^a   Shinoda, H ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Conjugated estrogens; Mammary carcinogenesis; Medroxyprogesterone acetate; Rats

Indexed keywords

CONJUGATED ESTROGEN; DIMETHYLBENZ[A]ANTHRACENE; MEDROXYPROGESTERONE ACETATE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER RISK; CARDIOVASCULAR DISEASE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; LONG TERM CARE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; SYMPTOM;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BONE DENSITY; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEDROXYPROGESTERONE 17-ACETATE; OVARIECTOMY; POSTMENOPAUSE; PROGESTERONE; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; THYMIDINE KINASE; THYMIDYLATE SYNTHASE;

EID: 0031427215     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Geist SH and Spielman F: The therapeutic value of amniotin in the menopause. Am J Obstet Gynecol 23: 697-701, 1932.
2. Harlap S: The benefits and risks of hormone replacement therapy: An epidemiologic overview. Am J Obstet Gynecol 166: 1986-1992, 1992.
3. Herzfeld A, Legg MA and Greengard O: Human colon tumors: Enzymic and histological characteristics. Cancer 42: 1280-1283, 1978.
4. Weber G, Lui MS, Takeda E and Denton JE: Enzymology of human colon tumor. Life Sci 27: 793-799, 1980.
5. Sakamoto S, Abe A, Kudo H, Yamada N, Seki K and Okamoto R: Effects of estrogen and progesterone on thymidine kinase activity in the immature rat uterus. Am J Obstet Gynecol 145: 711-715, 1983.
6. Sakamoto S, Kuwa K, Tsukada K, Sagara T, Kasahara N and Okamoto R: Relative activities of thymidylate synthetase and thymidine kinase in 1,2-dimethylhydrazine-induced colon carcinoma in rats. Carcinogenesis 8: 405-408, 1987.
7. Sakamoto S, Mori T, Singtipop T, Kawashima S, Suzuki S, Kudo H, Sawaki K and Nagasawa H: Increase of DNA synthesis in uterine adenomyosis in mice with ectopic pituitary isograft. Acta Anat 145: 162-166, 1992.
8. Dunlap RB, Harding NGL and Huennekens FM: Thymidylate synthetase from amethopterin-resistant Lactobacillus casei. Biochemistry 10: 88-97, 1971.
9. Taylor AT, Stafford MA and Jones OW: Properties of thymidine kinase partially purified from human fetal and adult tissue. J Biol Chem 247: 1930-1935, 1972.
10. Shoji K, Horiuchi H and Shinoda H: Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodont Res 30: 277-284, 1995.
11. Smith DC, Prentice R and Thompson DJ: Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293: 1164-1167, 1975.
12. Gambrell RDJr: Prevention of endometrial cancer with progestins. Maturitas 8: 159-168, 1986.
13. L'Hermite ML: Risk of estrogens and progestogens. Maturitas 12: 215-246, 1990.
14. Bergkvist L, Adami HO, Persson I, Hoover R and Schairer C: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Eng J Med 321: 293-297, 1989.
15. Ewertz M: Influence of noncontraceptive exogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 421: 832-838, 1988.
16. Mills PK, Beeson WL, Phillip RL and Fraser GE: Prospective study of exogenous hormone use and breast cancer in SeventhDay Adventists. Cancer 64: 591-597, 1989.
17. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA and Rossing MA: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274: 137-142, 1995.
18. Pannuti F, Martoni A, Cilenti G, Camaggi CM, Fruet F and other investigators: Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. Eur J Cancer Clin Oncol 24: 423-429, 1988.
19. Kalu DN: The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15: 175-192, 1991.